KMT2A and leukemia: Chen et al. reported that miR-196b directly targeted both the HOXA9/MEISI oncogenes and FAS tumor suppressor in MLL-rearranged leukemia, and the oncogenic role of miR-196b prevails over its tumor-suppressor role [42].